MedPacto Officially Invited to JP Morgan Healthcare Conference... "Technology Transfer in Full Swing"
Official Invitation to JP Morgan Healthcare Conference
Seeking Technology Transfer and Partnership for Baektoseoptip
[Asia Economy Reporter Eunmo Koo] MedPacto, a biomarker-based innovative drug development company, announced on the 15th that it has been officially invited to participate in the 'JP Morgan Healthcare Conference 2021,' which will be held online in January next year.
MedPacto is scheduled to hold online meetings with multinational pharmaceutical companies at the 'JP Morgan Healthcare Conference,' which will be held online from the 11th to the 14th of next month. MedPacto is expected to accelerate the discovery of strategic partnerships, including the technology transfer of Bactosertib, at this conference.
MedPacto's main pipeline, 'Bactosertib,' is a new drug candidate that inhibits the signaling of transforming growth factor TGF-β, which impedes the therapeutic effect of immune checkpoint inhibitors. Bactosertib selectively inhibits TGF-β signaling, improving the tumor microenvironment to enable immune cells to attack cancer cells.
Bactosertib can be combined with various therapies such as immune checkpoint inhibitors and chemotherapy, and a total of 11 clinical trials are underway. Currently, it is being administered in combination with immune checkpoint inhibitors for the treatment of colorectal cancer, gastric cancer, and non-small cell lung cancer, and combination clinical trials with targeted anticancer drugs are also being conducted for the treatment of desmoid tumors. In particular, Bactosertib's potential to expand to various indications, including major cancers and rare cancers, increases its value as a new drug.
Starting with the American Society of Clinical Oncology (ASCO) in May this year, MedPacto has presented promising clinical results of combination therapies for desmoid tumors, gastric cancer, and non-small cell lung cancer at several conferences, including the European Society for Medical Oncology (ESMO).
Especially, the results of the phase 2a combination clinical trial of Bactosertib and Imfinzi, presented at the Society for Immunotherapy of Cancer (SITC2020) in November, attracted the attention of global big pharma companies due to its groundbreaking therapeutic effect compared to the global standard of care. The development achievements of VRGS, a biomarker of Bactosertib presented together, seem to have been an opportunity to highly evaluate Bactosertib's commercialization potential as a biomarker-based innovative drug.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "No Cure Available, Spread Accelerates... Already 105 Dead, American Infected"
- "If That's the Case, Why Not Just Buy Stocks?" ETFs in Name Only, Now 'Semiconductor-Heavy' and a Playground for Short-Term Traders
- "Reporters Who First Revealed Jo Jinwoong's Juvenile Offense History Cleared of Juvenile Act Violation"
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
A MedPacto official said, "Based on the excellent results presented at numerous global conferences, discussions for technology transfer will also begin in earnest at this JP Morgan Healthcare Conference."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
